You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華潤雙鶴(600062.SH):全資孫公司的DC05F01獲批開展單藥在實體瘤患者中的臨牀試驗
格隆匯 04-06 17:04

格隆匯4月6日丨華潤雙鶴(600062.SH)公佈,近日,華潤雙鶴藥業股份有限公司全資孫公司北京雙鶴潤創科技有限公司收到了國家藥品監督管理局頒發的DC05F01《藥物臨牀試驗批准通知書》(通知書編號:2022LP00558),獲批該藥品開展單藥在實體瘤患者中的臨牀試驗。

DC05F01為“first-in-class”藥物,目前暫無同類產品的研發信息。截至目前,公司DC05F01相關研發項目累計已投入研發費用約1.49億元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account